Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

13.99 -1.89

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.1

Max

14.56

Chiffres clés
By Trading Economics
Revenu	-1.4M -14M
BPA	-0.15
Employés	37
EBITDA	312K -12M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+118.38% upside

Dividendes
By Acuity
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-161M 1.2B
Ouverture précédente	15.88
Clôture précédente	13.99

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 juil. 2026, 23:56 UTC

Fair Isaac Corp shares are higher in after-market trading, supported by positive investor sentiment and a notable rise in the Nikkei 225 Index.

21 juil. 2026, 23:56 UTC

Ulta Beauty Inc. shares are lower in after-market trading, reflecting broader market trends despite positive sentiment from the Nikkei 225 Index surge.

21 juil. 2026, 23:56 UTC

American Electric Power shares are lower in after-market hours, continuing a three-session decline and remaining below the 20-day moving average.

21 juil. 2026, 23:56 UTC

Mondelez International shares declined in after-market trading, continuing a trend of four consecutive lower daily closes despite earlier gains during the session.

21 juil. 2026, 23:56 UTC

Northern Trust shares are higher in after-market trading, reflecting broader positive trends in regional equity indices and renewed investor optimism.

21 juil. 2026, 23:56 UTC

Dorian LPG Ltd shares are trading higher in after-market hours, reflecting a gradual increase since Tuesday's close amid broader positive trends in regional equity indices.

21 juil. 2026, 23:56 UTC

Macro News

ETF Constituents

Correlated Moves

U.S. stock markets rebounded, with the Financial Select Sector SPDR Fund roughly flat in after-hours trading, supported by contributions from SCHW, ICE, FISV, AON, and AXP.

21 juil. 2026, 23:56 UTC

No specific news was identified for Alnylam Pharmaceuticals during after-market hours. The stock remains near unchanged since Tuesday's close.

21 juil. 2026, 23:56 UTC

Phillips 66 shares are higher in after-market trading, with no specific news identified. Broader market momentum reflects positive investor sentiment amid easing geopolitical tensions.

21 juil. 2026, 23:56 UTC

Shake Shack Inc. shares are higher in after-market trading, reflecting a modest gain amid positive sentiment from broader market trends, including a rise in the Nikkei 225 Index.

21 juil. 2026, 23:56 UTC

Diamondback Energy Inc shares are lower in after-market hours, continuing a decline since Tuesday's close. Trading has reflected overall weaker performance without specific news.

21 juil. 2026, 23:56 UTC

Lumen Technologies Inc. shares are higher in after-market hours, reflecting a modest gain amid broader market weakness and positive sentiment in regional equity indices.

21 juil. 2026, 23:56 UTC

Baidu Inc. shares declined in after-market trading, retracing from an early session peak and remaining below recent averages. No specific news was identified.

21 juil. 2026, 23:56 UTC

Southern Copper Corp shares are lower in after-market trading, retracing from earlier gains while remaining above their 20-day moving average.

21 juil. 2026, 23:56 UTC

Entegris Inc shares are higher in after-market trading, reflecting a notable gain since Tuesday's close amid positive sentiment in regional equity indices.

21 juil. 2026, 23:56 UTC

ETF Constituents

Health Care Select Sector SPDR Fund declines after market close, driven by negative returns from Merck, Amgen, and Eli Lilly. The ETF remains near its one-month trading range.

21 juil. 2026, 23:52 UTC

Kratos Defense shares are higher in after-market trading, rebounding from earlier losses despite no specific news to explain the movement.

21 juil. 2026, 23:51 UTC

Japan's Trade Deficit Expected at -120 Billion Yen Amid Ongoing Economic Challenges and Investor Caution.

21 juil. 2026, 23:51 UTC

Japan's June export growth forecasted at 0.186%, crucial for GDP amid stable market expectations and global supply chain challenges.

21 juil. 2026, 23:51 UTC

Brazil's Central Bank Signals Potential Interest Rate Cuts Amid Lower Inflation Expectations Ahead of Key COPOM Meeting on July 27, 2026.

21 juil. 2026, 23:51 UTC

iShares Core U.S. Aggregate Bond ETF is trading higher in after-market hours amid a general upward trend in global equity indices and positive sentiment in fixed income.

21 juil. 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

21 juil. 2026, 23:51 UTC

Yum China Holdings Inc. shares rose in after-market trading, buoyed by positive market sentiment following earnings reports from Tesla and Broadcom.

21 juil. 2026, 23:51 UTC

Recursion Pharmaceuticals Inc's shares are lower in after-market hours, settling down from Tuesday's close without any specific news to explain the movement.

21 juil. 2026, 23:51 UTC

Zeta Global Holdings is higher in after-market trading, amid broader market strength following positive earnings from companies like Tesla and Broadcom.

21 juil. 2026, 23:51 UTC

Intercontinental Exchange Inc shares are higher in after-market hours amid increased trading activity, remaining above their 20-day moving average and near a one-month high.

21 juil. 2026, 23:51 UTC

Coca-Cola Europacific Partners PLC shares are lower in after-market hours amid notable volatility, with no specific company news identified to explain the movement.

21 juil. 2026, 23:51 UTC

Starwood Property Trust shares rose in after-market trading amid positive market sentiment following earnings reports from companies like Tesla and Broadcom.

21 juil. 2026, 23:51 UTC

NetEase Inc. shares are higher in after-market trading, reflecting positive sentiment from recent earnings reports of firms like Tesla and Broadcom.

21 juil. 2026, 23:51 UTC

Correlated Moves

Nexgen Energy Ltd shares advanced in after-market trading, buoyed by positive sentiment following earnings reports from major companies like Tesla and Broadcom.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

118.38% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD 118.38%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.